Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levocetirizine Dihydrochloride

FDA-approved product (tablet, oral), marketed as Levocetirizine Dihydrochloride, Levocetirizine Hydrochloride, Xyzal and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Levocetirizine Dihydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic disease
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Skin disease
  • Urticaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Piperazine derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Levocetirizine Dihydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levocetirizine Dihydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Traditional vs. Posterior Nasal Radiofrequency Ablation for Chronic Rhinitis

    NCT07323888 · start 2026-03-01

    Registered record
    Registry ID
    NCT07323888
    Conditions
    Nasal Obstruction; Chronic Rhinitis; Nonallergic Rhinitis; Rhinorrhea; Inferior Turbinate Hypertrophy
    Interventions
    Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation; Traditional Radiofrequency Ablation of Inferior Turbinates
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2026-03-01
    Completion
    2027-05-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasal Obstruction; Chronic Rhinitis; Nonallergic Rhinitis; Rhinorrhea +1 more
    InterventionTraditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation; Traditional Radiofrequency Ablation of Inferior Turbinates
    PhaseNot applicable
    Registry statusActive not recruiting

  • Steroid Use in Treatment of Allergic Reactions to Food

    NCT07341776 · start 2026-01-26

    Registered record
    Registry ID
    NCT07341776
    Conditions
    Anaphylactic Reaction; Anaphylaxis; Allergy in Children; IgE Mediated Food Allergy
    Interventions
    Antihistamines; Systemic corticosteroids; Adrenaline (rescue medication)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-01-26
    Completion
    2026-12
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaphylactic Reaction; Anaphylaxis; Allergy in Children; IgE Mediated Food Allergy
    InterventionAntihistamines; Systemic corticosteroids; Adrenaline (rescue medication)
    PhasePhase 4
    Registry statusRecruiting

  • Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

    NCT07299695 · start 2026-01-25

    Registered record
    Registry ID
    NCT07299695
    Conditions
    Idiopathic Pulmonary Fibrosis; Acute Exacerbation of Idiopathic Pulmonary Fibrosis
    Interventions
    Intravenous immunoglobulin (IVIG); Usual treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-01-25
    Completion
    2028-12
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis; Acute Exacerbation of Idiopathic Pulmonary Fibrosis
    InterventionIntravenous immunoglobulin (IVIG); Usual treatment
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria

    NCT07365683 · start 2025-08-18

    Registered record
    Registry ID
    NCT07365683
    Conditions
    Chronic Spontaneous Urticaria (CSU)
    Interventions
    tab bilastine 20 mg; tab bilastine 20 mg + tab levocetrizine 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-08-18
    Completion
    2026-01-17
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Spontaneous Urticaria (CSU)
    Interventiontab bilastine 20 mg; tab bilastine 20 mg + tab levocetrizine 5 mg
    PhaseNot applicable
    Registry statusCompleted

  • A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC

    NCT06632405 · start 2025-04-01

    Registered record
    Registry ID
    NCT06632405
    Conditions
    Breast Cancer
    Interventions
    Camrelizumab; Nab paclitaxel; Levocetirizine Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-04-01
    Completion
    2027-03-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionCamrelizumab; Nab paclitaxel; Levocetirizine Hydrochloride
    PhasePhase 2
    Registry statusNot yet recruiting

  • Treatment Options for Chronic Urticaria

    NCT06816784 · start 2025-02

    Registered record
    Registry ID
    NCT06816784
    Conditions
    Chronic Urticaria
    Interventions
    Autologous serum therapy; Oral levocetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-02
    Completion
    2025-07
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Urticaria
    InterventionAutologous serum therapy; Oral levocetirizine
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Phase I Study of LY3471851 in Healthy Participants

    NCT05565729 · start 2022-10-05

    Registered record
    Registry ID
    NCT05565729
    Conditions
    Healthy
    Interventions
    LY3471851; Placebo; Levocetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-10-05
    Completion
    2023-02-23
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLY3471851; Placebo; Levocetirizine
    PhasePhase 1
    Registry statusCompleted

  • A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

    NCT04699604 · start 2021-04-28

    Registered record
    Registry ID
    NCT04699604
    Conditions
    Allergic Asthma
    Interventions
    Levocetirizine Dihydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-04-28
    Completion
    2026-04-26
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Asthma
    InterventionLevocetirizine Dihydrochloride; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Tranexamic Acid and Spontaneous Chronic Urticaria

    NCT03789422 · start 2019-12-10

    Registered record
    Registry ID
    NCT03789422
    Conditions
    Chronic Spontaneous Urticaria
    Interventions
    association of levocetirizine and tranexamic acid; Levocetirizine only
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-12-10
    Completion
    2022-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Spontaneous Urticaria
    Interventionassociation of levocetirizine and tranexamic acid; Levocetirizine only
    PhasePhase 4
    Registry statusUnknown

  • Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.

    NCT04399525 · start 2019-10-28

    Registered record
    Registry ID
    NCT04399525
    Conditions
    Pruritus
    Interventions
    Desloratadine Single Dose; Levocetirizine Single Dose; Desloratadine Fourfold Dose; Levocetirizine Fourfold Dose
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-10-28
    Completion
    2020-03-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPruritus
    InterventionDesloratadine Single Dose; Levocetirizine Single Dose; Desloratadine Fourfold Dose; Levocetirizine Fourfold Dose
    PhaseNot applicable
    Registry statusCompleted

  • COrticosteroids in acUte uRticAria in emerGency dEpartment

    NCT03545464 · start 2019-09-21

    Registered record
    Registry ID
    NCT03545464
    Conditions
    Urticaria; Angiœdema
    Interventions
    Placebo Oral Tablet; Cortancyl Oral Tablet; Levocetirizine Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-21
    Completion
    2025-09-17
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrticaria; Angiœdema
    InterventionPlacebo Oral Tablet; Cortancyl Oral Tablet; Levocetirizine Oral Tablet
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)

    NCT03555890 · start 2018-05-18

    Registered record
    Registry ID
    NCT03555890
    Conditions
    Rhinitis
    Interventions
    Levocetirizine IRT 5 mg; Levocetirizine ODT 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-18
    Completion
    2018-09-17
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis
    InterventionLevocetirizine IRT 5 mg; Levocetirizine ODT 5 mg
    PhasePhase 1
    Registry statusCompleted

  • PK and Safety Study of HCP1102, HGP0813 and HGP1408

    NCT03371849 · start 2017-07-19

    Registered record
    Registry ID
    NCT03371849
    Conditions
    Healthy
    Interventions
    montelukast and levocetirizine FDC; Singulair + xyzal
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-07-19
    Completion
    2017-08-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionmontelukast and levocetirizine FDC; Singulair + xyzal
    PhasePhase 1
    Registry statusCompleted

  • To Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria

    NCT03250143 · start 2016-12-06

    Registered record
    Registry ID
    NCT03250143
    Conditions
    Chronic Refractory Urticaria
    Interventions
    cyclosporine vs azathioprine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-12-06
    Completion
    2017-11
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Refractory Urticaria
    Interventioncyclosporine vs azathioprine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria

    NCT02372604 · start 2015-07

    Registered record
    Registry ID
    NCT02372604
    Conditions
    Chronic Spontaneous Urticaria
    Interventions
    Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.; Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-07
    Completion
    2016-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Spontaneous Urticaria
    InterventionLevocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.; Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.
    PhasePhase 3
    Registry statusCompleted